In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aspect Medical nets $105.6mm in convertible debt financing

Executive Summary

Brain monitoring device maker Aspect Medical Systems has netted $105.6mm by selling 2.5% seven-year senior notes to institutional investors under Rule 144A. The notes convert into stock at a rate of 52.4294 shares per $1k notes, or $19.07 per share. (The shares averaged $16.01 at announcement.) Backers also received an option to purchase another $15mm in notes. Aspect plans to use the money to buy back some of its shares sold to Boston Scientific through a 2002 deal that was recently terminated.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Monitoring Equipment & Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies